Stockscreener 앱 받기
1.08
6.90%
-0.08
전일 마감가:
$1.16
열려 있는:
$1.098
하루 거래량:
19,814
Relative Volume:
1.35
시가총액:
$12.63M
수익:
$3.37M
순이익/손실:
$-57.28M
주가수익비율:
-0.1004
EPS:
-10.7522
순현금흐름:
$-51.83M
1주 성능:
-15.62%
1개월 성능:
-17.56%
6개월 성능:
-28.00%
1년 성능:
-39.66%
1일 변동 폭
$0.972
$1.17
1주일 범위
$0.972
$1.28
52주 변동 폭
$0.972
$1.96
신로직 Stock (SYBX) Company Profile
명칭
Synlogic Inc
전화
617-659-2802
주소
PO BOX 30, WINCHESTER, MA
SYBX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SYBX
Synlogic Inc
|
1.08 | 12.63M | 3.37M | -57.28M | -51.83M | -10.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
신로직 Stock (SYBX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-11-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-08-21 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2019-04-30 | 개시 | Jefferies | Buy |
| 2018-12-13 | 개시 | Chardan Capital Markets | Buy |
| 2018-03-19 | 개시 | H.C. Wainwright | Buy |
| 2018-01-29 | 개시 | Piper Jaffray | Overweight |
모두보기
신로직 주식(SYBX)의 최신 뉴스
Synlogic’s executive Mary Beth Dooley sells $172 in common stock - Investing.com India
SYBX stock touches 52-week low at $1.14 amid market challenges - Investing.com India
5 Best Microbiome Companies (April 2025) - Securities.io
Gallium Arsenide Market Applications and Semiconductor Industry Impact - openPR.com
Synlogic (NASDAQ:SYBX) Shares Pass Below Fifty Day Moving Average – Here’s Why - Defense World
SYBX stock touches 52-week low at $1.15 amid market challenges - Investing.com Australia
Synlogic (SYBX) to Release Quarterly Earnings on Tuesday - Defense World
Synlogic Inc. (SYBX) reports earnings - Quartz
Week Ahead (Nov.2226): FDA Decision, Data Presentations (ABEO, SYBX, AADI…) - RTTNews
CRISPR and Cas Gene Market May Set a New Epic Growth Story | Fate Therapeutics, Cellectis, Synlogic - Newstrail
Microbiomes Market to Grow by USD 824.3 Million (2025-2029) with Rising Disease Prevalence Boosting the Market, Report on How AI is Redefining Market LandscapeTechnavio - The Malaysian Reserve
Synlogic's executive sells shares worth $2,802 - MSN
Synlogic's executive sells shares worth $2,802 By Investing.com - Investing.com South Africa
Promising Growth Expected in Gout Therapeutics Market, Set to Reach $5.03 Billion by 2029 with a CAGR of 11.7% - WhaTech
Synlogic (SYBX) Stock Price, News & Analysis - MarketBeat
Synlogic announces board member resignation By Investing.com - Investing.com Canada
Synlogic announces board member resignation - Investing.com
The definitive Boston biotech layoff tracker for 2024 - The Business Journals
Fmr LLC Trims Stock Holdings in Synlogic, Inc. (NASDAQ:SYBX) - Defense World
Biopolymers Market to Reach USD 47.4 Billion by 2032 Driven - GlobeNewswire
Synlogic (NASDAQ:SYBX) Trading Down 0.7% – What’s Next? - Defense World
Only the paranoid survive, and the CEO’s paradox, from Aoife Brennan - BioCentury
Urea Cycle Disorder Treatment Market to Grow by USD 215.4 Million (2024-2028), Driven by Rising Prevalence, with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
Synlogic (FRA:MIN) 3-Year FCF Growth Rate : 21.90% (As of Sep. 2024) - GuruFocus.com
Synlogic (FRA:MIN) Momentum Rank : 2 (As of Nov. 30, 2024) - GuruFocus.com
Phenylketonuria Market size is ~700 USD million in 2023, asserts DelveInsight | Pharma Giants: PTC Therapeutics, Homology Medicines, Synlogic, BioMarin Pharmaceuticals - The Globe and Mail
Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Rising Disease Prevalence Driving Revenue, with AI Powering Market EvolutionTechnavio - The Malaysian Reserve
Synlogic Third Quarter 2024 Earnings: US$0.01 loss per share (vs US$2.57 loss in 3Q 2023) - Yahoo Finance
Synlogic Reports Q3 2024 Financial Outcomes - TipRanks
Synlogic Reports Third Quarter 2024 Financial Results - GlobeNewswire
Synlogic (SYBX) Slashes Q3 Losses by 99% Amid Strategic Review, No Revenue | SYBX Stock News - StockTitan
The 2024 Biotech Graveyard - Fierce Biotech
Synlogic's head of finance Mary Beth Dooley sells $110 in stock - Investing.com
(PDF) The effects of caffeinated and decaffeinated coffee on sex hormone-binding globulin and endogenous sex hormone levels: A randomized controlled trial - ResearchGate
Oxygen Scavenger Market Set to Reach USD 8.2 Billion by - GlobeNewswire
Synlogic says co entered into sales agreement with Cowen And Company, LLC - Reuters
Renaissance Technologies LLC Decreases Position in Synlogic, Inc. (NASDAQ:SYBX) - Defense World
Urea Cycle Disorders Treatment Market Research In New Report - WhaTech
Synlogic Reports Second Quarter 2024 Financial Results - GlobeNewswire
Otsuka snaps up Jnana with its phenylketonuria drug for $800m - Pharmaceutical Technology
Xilio Therapeutics Appoints Aoife Brennan and James Shannon to its Board of Directors - citybiz
Gut Microbiota Market Set to Reach a Staggering US$ 3,600.1 Million by 2032 - BioSpace
Synlogic Announces Termination Of Abbvie Collaboration Agreement - Reuters
Synlogic Reports First Quarter 2024 Financial Results - GlobeNewswire
Human Microbiome Market Size & Share to Surpass USD 2,555 million by 2030 - WhaTech
Synlogic Appoints James Flynn to Board Amidst Director Resignations - TipRanks
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewswire
Synlogic Announces Top Executive Departures and Compensation Deals - TipRanks
Synlogic adopts shareholder rights plan, eyes strategic options By Investing.com - Investing.com Canada
Irish-led Synlogic to cease operations after ending drug trial - Silicon Republic
Synlogic Announces Plan to Cease Operations and Reduce Its Workforce by More Than 90% - SynBioBeta
신로직 (SYBX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):